OR52L1 inhibitors belong to a class of chemical compounds that specifically target and inhibit the activity of the olfactory receptor 52L1 (OR52L1). Olfactory receptors, such as OR52L1, are G-protein-coupled receptors (GPCRs) primarily known for their role in the detection of odorants. These receptors are part of a large gene family, with hundreds of distinct olfactory receptors that interact with various chemical compounds, contributing to the sense of smell. OR52L1 is one such receptor, and although traditionally associated with olfaction, it is now known to be expressed in tissues outside the nasal epithelium, which suggests it may play additional biological roles. Inhibitors of OR52L1 act by binding to the receptor and blocking its ability to interact with its ligands, thereby modulating signaling pathways activated by this receptor. The design and study of OR52L1 inhibitors are often focused on elucidating the molecular mechanisms of receptor-ligand interactions and understanding the broader physiological functions that the receptor may mediate.
From a chemical perspective, OR52L1 inhibitors can vary widely in their structural properties. Many of these inhibitors are small molecules that are designed or discovered through high-throughput screening techniques or rational drug design. Structural studies often explore the active sites or binding domains of OR52L1 to understand how inhibitors interact with specific amino acid residues within the receptor. The inhibitors can be classified based on their chemical scaffolds, which may include heterocyclic compounds, aromatic rings, or aliphatic chains with functional groups that enhance receptor affinity. Inhibitors can be competitive or non-competitive, depending on how they interfere with ligand binding or signal transduction. Characterizing these inhibitors involves the use of advanced biochemical techniques such as molecular docking, mutagenesis studies, and receptor binding assays. These research efforts provide valuable insights into the structural and functional dynamics of OR52L1, contributing to our broader understanding of GPCR regulation and signal transduction mechanisms in biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may downregulate OR52L1 expression by causing DNA demethylation at the gene's promoter, therefore disrupting the transcriptional repression usually maintained by methylation. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A could decrease OR52L1 expression by enhancing histone acetylation, which could lead to chromatin remodeling that renders the OR52L1 promoter less accessible to transcriptional machinery. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin A has the potential to reduce OR52L1 expression by binding to G-C rich DNA sequences within the promoter region, obstructing the essential transcription factors from initiating gene transcription. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D may inhibit OR52L1 expression by intercalating into DNA, which prevents the advancement of RNA polymerase along the OR52L1 coding region, thus hindering mRNA synthesis. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG 108 could downregulate OR52L1 by inhibiting DNA methyltransferases, leading to reduced methylation levels at the OR52L1 gene promoter and subsequent transcriptional suppression. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
5-Aza-2′-Deoxycytidine (Decitabine) may lead to OR52L1 downregulation by hypomethylating cytosine bases in the DNA, particularly at the gene promoter, which often silences gene activity through chromatin compaction. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate can lead to the suppression of OR52L1 expression by increasing histone acetylation, thus creating a state of chromatin that is less favorable for the binding of transcriptional activators. | ||||||
MS-275 | 209783-80-2 | sc-279455 sc-279455A sc-279455B | 1 mg 5 mg 25 mg | $24.00 $90.00 $212.00 | 24 | |
MS-275 (Entinostat) may decrease OR52L1 expression levels by selectively inhibiting class I histone deacetylases, resulting in altered acetylation patterns that can silence gene transcription. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
Suberoylanilide Hydroxamic Acid (Vorinostat) could suppress OR52L1 by inhibiting histone deacetylase activity, thereby increasing the acetylation of histones associated with the OR52L1 gene and altering gene expression patterns. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin may inhibit OR52L1 expression by strongly inhibiting RNA polymerase II, which is necessary for the transcription of mRNA from the OR52L1 gene, thereby reducing its overall expression. | ||||||